−3.5SEK
−45.95 MSEK
126.61 MSEK
8.93 M
About DEVYSER DIAGNOSTICS AB
Sector
Industry
CEO
Fredrik Alpsten
Website
Headquarters
Hägersten
Employees (FY)
92
Founded
2004
ISIN
SE0016588867
FIGI
BBG013X97TG8
Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. Its products are used for complex DNA testing in the areas of hereditary diseases, oncology and post-transplantation monitoring. The firm's products are also used in treating cancer patients and in follow-up transplant patients. The company was founded by Anders Hedrum, Ulf Axel Klangby and Dan Hauzenberger in 2004 and is headquartered in Hägersten, Sweden.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of DVYSR is 104.5 SEK — it has increased by 1.95% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange DEVYSER DIAGNOSTICS AB stocks are traded under the ticker DVYSR.
DEVYSER DIAGNOSTICS AB is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
DVYSR stock is 2.44% volatile and has beta coefficient of 0.57. Check out the list of the most volatile stocks — is DEVYSER DIAGNOSTICS AB there?
DVYSR earnings for the last quarter are −0.40 SEK per share, whereas the estimation was −0.48 SEK resulting in a 15.79% surprise. The estimated earnings for the next quarter are −0.50 SEK per share. See more details about DEVYSER DIAGNOSTICS AB earnings.
DEVYSER DIAGNOSTICS AB revenue for the last quarter amounts to 46.70 M SEK despite the estimated figure of 43.07 M SEK. In the next quarter revenue is expected to reach 45.60 M SEK.
Yes, you can track DEVYSER DIAGNOSTICS AB financials in yearly and quarterly reports right on TradingView.
DVYSR stock has fallen by 1.42% compared to the previous week, the month change is a 1.42% fall, over the last year DEVYSER DIAGNOSTICS AB has showed a 19.02% increase.
DVYSR net income for the last quarter is −6.00 M SEK, while the quarter before that showed −14.60 M SEK of net income which accounts for 58.90% change. Track more DEVYSER DIAGNOSTICS AB financial stats to get the full picture.
No, DVYSR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, DVYSR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DEVYSER DIAGNOSTICS AB stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 92.00 employees. See our rating of the largest employees — is DEVYSER DIAGNOSTICS AB on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DEVYSER DIAGNOSTICS AB technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DEVYSER DIAGNOSTICS AB stock shows the buy signal. See more of DEVYSER DIAGNOSTICS AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on DEVYSER DIAGNOSTICS AB future price: according to them, DVYSR price has a max estimate of 128.00 SEK and a min estimate of 120.00 SEK. Read a more detailed DEVYSER DIAGNOSTICS AB forecast: see what analysts think of DEVYSER DIAGNOSTICS AB and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DEVYSER DIAGNOSTICS AB EBITDA is −57.79 M SEK, and current EBITDA margin is −38.53%. See more stats in DEVYSER DIAGNOSTICS AB financial statements.